Immunogenicity and safety of the quadrivalent human papillomavirus vaccine

alkiviadis.1961 shared this article with you from Inoreader Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26  years: A phase 3, open-label, immunobridging study. Via Vaccine CONCLUSION: Antibody responses induced by the 3-dose qHPV vaccination regimen in Chinese girls aged 9-19 years were non-inferior to those in Chinese young women aged 20-26 years. The vaccine was generally well tolerated in the study population. ClinicalTrials.gov Identifier: NCT03493542. PMID: 33239228 [PubMed - as supplied by publisher] (Source: Vaccine) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.